The Potential Role of Fosfomycin in Neonatal Sepsis Caused by Multidrug-Resistant Bacteria

• Published in: Drugs (New York, N.Y.) Vol. 77; no. 9; pp. 941 - 950
• Main Authors: Li, Grace, Standing, Joseph F., Bielicki, Julia, Hope, William, van den Anker, John, Heath, Paul T., Sharland, Mike
• Format: Journal Article
• Language: English
• Published: Cham Springer International Publishing 01.06.2017; Springer Nature B.V
• Subjects: Anti-Bacterial Agents - administration & dosage; Anti-Bacterial Agents - adverse effects; Anti-Bacterial Agents - pharmacokinetics; Anti-Bacterial Agents - therapeutic use; Antibiotics; Antimicrobial agents; Bacteria; Bacteria - drug effects; Clinical outcomes; Clinical trials; Drug resistance; Drug Resistance, Multiple, Bacterial; E coli; Enterobacteriaceae; Escherichia coli; Fosfomycin; Fosfomycin - administration & dosage; Fosfomycin - adverse effects; Fosfomycin - pharmacokinetics; Fosfomycin - therapeutic use; Humans; Infant, Newborn; Internal Medicine; Klebsiella pneumoniae; Leading Article; Medical research; Medicine; Medicine & Public Health; Morbidity; Mortality; Multidrug resistance; Multidrug resistant organisms; Neonatal Sepsis - drug therapy; Neonatal Sepsis - microbiology; Neonates; Newborn babies; Pharmacokinetics; Pharmacology; Pharmacology/Toxicology; Pharmacotherapy; Pseudomonas aeruginosa; Sepsis; Staphylococcus; Staphylococcus infections; Urinary tract diseases; Urinary tract infections; Urogenital system; Klebsiella Species; Neonatal Sepsis; Late Preterm Infant; Preterm Infant; Fosfomycin

The broad-spectrum activity of fosfomycin, including against multidrug-resistant (MDR) strains, has led to renewed interest in its use in recent years. Neonatal sepsis remains a substantial cause of morbidity and mortality at a global level, with evidence that MDR bacteria play an increasing role. T...